secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001437749-24-018214
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen to present fasedienol and itruvone data at ASCP conference May 28-31
-----------------------------------------------------------------------------

- Poster on fasedienol (Phase 3 for social anxiety disorder) from PALISADE-2 trial on May 29.
- Poster on intranasal itruvone (Phase 2 for major depressive disorder) distribution in rats on May 29.
- Posters will be available on Vistagen website on June 3, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924018214/0001437749-24-018214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774924018214/vtgn20240523_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-018214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer